Sickle cell anaemia is a hematological disorder caused by a single amino acid substitution in the beta globin chain, resulting in abnormal hemoglobin S. Homozygotes (SS) have only HbS and experience sickle cell disease, while heterozygotes (AS) have a mixture of HbA and HbS and are asymptomatic carriers. Clinical features include painful vaso-occlusive crises involving bones and organs due to sickled red blood cells blocking small vessels. Management focuses on prevention, treatment of crises, blood transfusions, and increasing fetal hemoglobin levels to inhibit HbS polymerization.